Literature DB >> 16569382

Huntington's Disease.

Donald S Higgins1.   

Abstract

Although available treatments for Huntington's disease (HD) are imperfect, thoughtful application can positively impact quality of life. Dopamine antagonists can provide control of the troublesome hyperkinetic movements. These agents can also diminish the frequency of hallucinations and delusions when symptoms of psychosis occur. Classical neuroleptics have the widest utilization, although atypical antipsychotics are being increasingly used. Suppression of choreiform movements has also been reported with amantadine and tetrabenazine, which is not currently approved in the United States but under investigation. Alteration in mood can be successfully managed with a variety of antidepressant medications. Superior tolerability and value in the management of a variety of behavioral disturbances have lead to extensive use of serotonin reuptake inhibitors. Modest disturbance of mood can sometimes be addressed with anticonvulsant medications. Considered a manifestation of advanced disease, dementia is less commonly addressed therapeutically. However, gathering experience suggests improved cognitive function can occur with cholinesterase inhibitor therapy. Frequently overlooked is the value of rehabilitation services in the management of diverse symptoms. Although the value of a dysphagia evaluation is apparent, the benefit to be derived from physical and occupational therapy involvement cannot be overstated. Current therapeutic trials will undoubtedly provide additional therapies to moderate symptoms, but once the mechanism(s) of selective striatal projection neuron degeneration are delineated, a revolution in the management of HD will occur.

Entities:  

Year:  2006        PMID: 16569382     DOI: 10.1007/s11940-006-0014-x

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.972


  45 in total

Review 1.  Palliative care for people with late-stage Huntington's disease.

Authors:  C B Moskowitz; K Marder
Journal:  Neurol Clin       Date:  2001-11       Impact factor: 3.806

2.  Improvement of Huntington's disease with olanzapine and valproate.

Authors:  V E Grove; J Quintanilla; G T DeVaney
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

3.  Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study.

Authors: 
Journal:  Neurology       Date:  2003-12-09       Impact factor: 9.910

4.  Long-term effects of tetrabenazine in hyperkinetic movement disorders.

Authors:  J Jankovic; J Beach
Journal:  Neurology       Date:  1997-02       Impact factor: 9.910

5.  A comparison of the frequency of major affective disorder in Huntington's disease and Alzheimer's disease.

Authors:  R H Mindham; C Steele; M F Folstein; J Lucas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-11       Impact factor: 10.154

6.  The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size.

Authors:  R R Brinkman; M M Mezei; J Theilmann; E Almqvist; M R Hayden
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

7.  Clinical issues associated with maintenance treatment of patients with schizophrenia.

Authors:  Sally K Guthrie
Journal:  Am J Health Syst Pharm       Date:  2002-09-01       Impact factor: 2.637

Review 8.  Huntington disease: genetics and epidemiology.

Authors:  P M Conneally
Journal:  Am J Hum Genet       Date:  1984-05       Impact factor: 11.025

9.  Psychiatric syndromes in Huntington's disease.

Authors:  E D Caine; I Shoulson
Journal:  Am J Psychiatry       Date:  1983-06       Impact factor: 18.112

10.  Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease.

Authors:  N G Ranen; O C Stine; M H Abbott; M Sherr; A M Codori; M L Franz; N I Chao; A S Chung; N Pleasant; C Callahan
Journal:  Am J Hum Genet       Date:  1995-09       Impact factor: 11.025

View more
  2 in total

Review 1.  Management of dysphagia in Huntington's disease: a descriptive review.

Authors:  Nicole Pizzorni; Francesca Pirola; Andrea Ciammola; Antonio Schindler
Journal:  Neurol Sci       Date:  2020-01-27       Impact factor: 3.307

2.  A Systematic Review of Rehabilitation for Corticobulbar Symptoms in Adults with Huntington's Disease.

Authors:  Emma Burnip; Emma Wallace; Kristin Gozdzikowska; Maggie-Lee Huckabee
Journal:  J Huntingtons Dis       Date:  2020
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.